Trump Says he Could Override FDA Vaccine Standards

US president Donald Trump has said he believes the White House could override the US Food and Drug Administration (FDA) if the national health watchdog goes ahead with mooted plans to toughen standards for approval of a Covid-19 vaccine or an Emergency Use Authorization.

“We're looking at that and that has to be approved by the White House,” Trump said, adding that it “sounds like a political move.” The president is said to believe that a pre-election authorization would translate into a victory for him. He has repeatedly promised that a vaccine would be ready by election day, which is Nov. 3.

While The FDA declined to comment on Trump's remarks, an FDA spokesperson told news broadcaster CNN that the agency’s guidelines must go through White House Office of Management and Budget review process.

Rumors of a move by the health agency to reassure the American public and the worried National Institutes of Health (NIH) that the first vaccines to be approved by the FDA will be safe surfaced earlier this week and speculation focused on tougher guidelines being  announced later in the week.

Without giving any details, FDA commissioner Stephen Hahn told the US Senate Health Committee on Sept. 23 that the "FDA will not authorize or approve a vaccine that we would not feel comfortable giving to our families.” It would have to meet the agency's “rigorous expectations” for safety and effectiveness, he said.

Hahn has come under fire from some in the health sector for repeatedly obliging the president’s requests for EUAs that many were skeptical about.

Peter Hotez, a vaccinologist at Baylor College of Medicine in Texas, told the broadcaster

he was concerned that “there could be a gray zone where a vaccine looks partially protective and it goes on the market without a full formal review process.”

US president Donald Trump thinks he could override any tougher standards the...
US president Donald Trump thinks he could override any tougher standards the Food and Drug Administration (FDA) could require for approving a Covid-19 vaccine or an Emergency Use Authorization (EUA). The president has promised voters a vaccine before the Nov. 3 election. (c) @realDonaldTrump

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.